Page last updated: 2024-08-24

imiquimod and bay 11-7082

imiquimod has been researched along with bay 11-7082 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Altavilla, D; Anastasi, GP; Arcoraci, V; Bitto, A; Cutroneo, G; Ettari, R; Irrera, N; Lentini, M; Minutoli, L; Pallio, G; Pizzino, G; Scuruchi, M; Squadrito, F; Vaccaro, M	1

Other Studies

1 other study(ies) available for imiquimod and bay 11-7082

Article	Year
BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis. Clinical science (London, England : 1979), 2017, Mar-01, Volume: 131, Issue:6 Topics: Aminoquinolines; Animals; Apoptosis; Cytokines; Dermatologic Agents; Drug Eruptions; Drug Evaluation, Preclinical; Imiquimod; Inflammasomes; Male; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Nitriles; NLR Family, Pyrin Domain-Containing 3 Protein; Psoriasis; RNA, Messenger; STAT3 Transcription Factor; Sulfones	2017

Article

Year

BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis.

Clinical science (London, England : 1979), 2017, Mar-01, Volume: 131, Issue:6

Topics: Aminoquinolines; Animals; Apoptosis; Cytokines; Dermatologic Agents; Drug Eruptions; Drug Evaluation, Preclinical; Imiquimod; Inflammasomes; Male; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Nitriles; NLR Family, Pyrin Domain-Containing 3 Protein; Psoriasis; RNA, Messenger; STAT3 Transcription Factor; Sulfones

2017